Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACIFIC2
2017-004397-34Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Mar 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Durvalumab + standard chemoradiation with Placebo + standard chemoradiation (2 arms). Primary endpoints: Progression-free survival and Objective response rate. Started Mar 2018; status: active.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2017-004397-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004397-34.